Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
enGene Holdings Inc. received a Schedule 13G disclosure from a group of Invus-affiliated investment entities and Raymond Debbane reporting passive ownership of its common shares. As of January 27, 2026, Invus Public Equities, L.P. directly held 3,675,408 common shares and Avicenna Life Sci Master Fund LP directly held 569,151 common shares. Through their control relationships, Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Mr. Debbane may each be deemed to beneficially own these holdings.
Mr. Debbane is reported as beneficial owner of 4,244,559 common shares, representing 6.3% of the class, based on 66,984,661 shares outstanding as of December 17, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of enGene, indicating a passive investment stance.
enGene Holdings Inc. entered into a Second Amendment to its loan and security agreement with Hercules Capital and other lenders, expanding its term loan facility from $50 million to up to $125 million, available in multiple milestone-based tranches. An initial $25 million Tranche 1 advance was funded on January 20, 2026 to refinance the prior term loans, and additional tranches of up to $35 million, $20 million, and $20 million are tied to defined clinical, approval and commercial milestones, plus an uncommitted $25 million tranche subject to lender approval.
The 2026 Term Loans mature on January 1, 2030 and bear interest at the greater of the prime rate plus 2.25% (capped at 10.25%) or 9.25%, with facility charges and a 5.95% end-of-term fee. The loans are secured by a senior lien on substantially all of the borrowers’ assets, including intellectual property. In connection with each loan advance, the lenders receive 2026 Warrants exercisable at $9.18 per share for seven years; on the Closing Date, they received 40,850 warrants, and the total potential issuance is capped at 204,248 warrants and underlying common shares if the full commitment is drawn.
enGene Holdings Inc. filed a current report describing a communication about its debt arrangements. The company announced that it entered into a Second Amendment to its Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. and other lenders. This amendment builds on the original agreement dated December 22, 2023 and a prior amendment dated December 18, 2024, together referred to as the Amended Loan Agreement.
The company issued a press release on January 20, 2026 explaining the updated loan terms, which is furnished as an exhibit to the report rather than filed. As an emerging growth company with common shares and warrants listed on Nasdaq, enGene is using this report primarily to provide investors with notice of the press release and the existence of the amended loan agreement.
enGene Holdings Inc. filed a Form S-8 to register securities for employee benefit plans and to reflect non-qualified stock options issued as inducements for hires. The filing notes Inducement Awards granted on April 2, 2025, June 16, 2025, and July 31, 2025, approved under the employment inducement exception to Nasdaq Listing Rule 5635(c)(4).
The document incorporates by reference the company’s Annual Report for the year ended October 31, 2024 (and Amendment No. 1), multiple quarterly reports for 2025, several Form 8-Ks, and exhibits including the amended 2023 Incentive Equity Plan and the 2025 Employee Stock Purchase Plan. Signatures are dated September 11, 2025.
enGene Holdings Inc. reports continued development spending and financing activity while evaluating its ability to continue as a going concern. The company has 100,000,000 authorized common shares with 51,105,807 and 50,976,676 shares issued and outstanding as of July 31, 2025 and October 31, 2024, respectively. The company drew a $22.5 million Tranche 1 term loan advance and has up to $50.0 million available in multiple tranches, subject to milestones and lender approval, with various prepayment fees and an end-of-term charge equal to 5.50% of principal. Operating expenses increased materially due to clinical and manufacturing activity: a $26.2 million increase in detalimogene direct expense and a $7.9 million increase in personnel-related costs year-to-date, with additional increases in G&A and professional fees related to commercialization preparations. The company identified material weaknesses in internal controls around IT change management, user access segregation, and account reconciliations and has implemented remediation steps including new policies, risk assessments, enhanced software controls, and engagement of an accounting firm. The filing emphasizes heavy dependence on the success of detalimogene and lists multiple clinical, regulatory, manufacturing, and financing risks that could affect future operations.
enGene Holdings Inc., a British Columbia company listed on The Nasdaq Stock Market LLC, furnished an update on its recent performance. The company announced its financial results for the third fiscal quarter ended July 31, 2025, and provided these details in a press release.
The press release, dated September 11, 2025, is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Securities Exchange Act of 1934, meaning it is not subject to certain liability provisions or automatically incorporated into other SEC filings. The report is signed by Chief Executive Officer and President Ronald H. W. Cooper.
enGene Holdings Inc. reported a clinical milestone and updated its investor materials. The company reached its target enrollment of 100 patients in Cohort 1, the pivotal cohort of the Phase 2 portion of the LEGEND trial evaluating detalimogene voraplasmid in high-risk, non-muscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin. Cohort 1 focuses on patients with carcinoma in-situ, with or without concomitant papillary disease. enGene also refreshed its Corporate Presentation and furnished it as an exhibit, while a press release describing the enrollment milestone was filed as a separate exhibit.